066 – Actinium Pharma’s Transformative Radiation Treatment. KPTI’s Selinexor Approved for DLBCL!

Actinium Pharma (#ATNM) is commercializing Antibody-Radiation Conjugates (ARC) for the treatment of diseases that require conditioning regimens (Bone Marrow Transplant, Stem Cell Transplant, Adoptive Cell Therapies). The current state of total body irradiation leaves patients with significant side effects and excludes a large demographic due to potential lethality of the conditioning treatment. ATNM is testing a targeted approach that could allow for substantially more patients to be treated and reduce side effects. I go through the details of the company and talk about why the risk/reward favors longs into the next catalyst.

Karyopharm (#KPTI) recently received news that their drug Selinexor (XPOVIO) is approved for 3L DLBCL, which should drive a nice amount of revenue for the company.

Link to myeloablative therapy costs: https://www.pharllc.com/wp-content/uploads/2017/11/10-2017_Cost.pdf

If you want to help the show, you can donate here: https://tips.pinecast.com/jar/breaking-biotech

You can also open an account at Tastyworks using my referral code: https://start.tastyworks.com/#/login?referralCode=ZWQ77XG2PZ

Follow me on twitter @matthewlepoire

Send me an email matthewlepoire@gmail.com

Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt’s opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

 

049 – Is Odonate’s Hype Overblown?

Today, I talk breast cancer and how Odonate’s oral Taxane (Tesataxel) could garner the attention of doctor’s looking to alleviate the burden of IV chemotherapy infusion in their patients. I discuss the latest macro news, biotech news, and compare previous Taxane revenue to see if my model is reasonable.

This is not investment advice, but for entertainment purposes. I am not liable for any losses you generate from trading.

 

044 – Marker Therapeutics DISAPPOINTS in pancreatic cancer

Hi all, today I talk about the #MRKR interim update of their MultiTAA treatment in pancreatic cancer. I go through the data in all 3 arms and analyze whether or not they see an actual effect of their unique therapy.

*this is not investment advice*

#breaking biotech #biotech

 

039 – Will Marker Therapeutics Succeed in Pancreatic Cancer?

Hi everybody, in this episode I take a deeper dive into pancreatic cancer and how Marker Therapeutics’ MultiTAA T Cell therapy might fare against it.

Thanks for watching!

Follow me on twitter @matthewlepoire

Note: *This is not investment advice*

 

029 – Powell ruins the market. DBVT pulls BLA!

Hey everybody, I hope you’ve all been enjoying the holidays. I talk about 3 things in this video:

1. The federal reserve and chairman Powell’s comments on their guidance and the economy.
2. DBVT pulling their BLA and my opinion on both them and AIMT.
3. CRISPR/Cas9 and the companies commercializing the tech.

*This is only my opinion and should not be considered financial advice*

http://www.breakingbiotech.com

#breakingbiotech #powell #dbvt #aimt

 
%d bloggers like this: